Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Maxcyte's Change in Receivables rose 1234761.9% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 22557.44%. This contributed to the annual value of -$1.2 million for FY2024, which is 7654.04% up from last year.
  • As of Q3 2025, Maxcyte's Change in Receivables stood at $2.6 million, which was up 1234761.9% from $238000.0 recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Change in Receivables registered a high of $4.0 million during Q4 2022, and its lowest value of -$3.4 million during Q1 2023.
  • Over the past 5 years, Maxcyte's median Change in Receivables value was $238000.0 (recorded in 2025), while the average stood at $182689.5.
  • Over the last 5 years, Maxcyte's Change in Receivables had its largest YoY gain of 4645555.56% in 2023, and its largest YoY loss of 29413.98% in 2023.
  • Maxcyte's Change in Receivables (Quarter) stood at $918900.0 in 2021, then surged by 336.63% to $4.0 million in 2022, then crashed by 141.25% to -$1.7 million in 2023, then surged by 107.37% to $122000.0 in 2024, then soared by 2008.2% to $2.6 million in 2025.
  • Its Change in Receivables stands at $2.6 million for Q3 2025, versus $238000.0 for Q2 2025 and $839000.0 for Q1 2025.